Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: InControl, Inc.

This article was originally published in The Gray Sheet

Executive Summary

InControl, Inc.: Receives FDA investigational device exemption for U.S. clinical trials of its Metrix atrial defibrillation system, "the first implantable device designed specifically for patients suffering from recurrent symptomatic episodes of atrial fibrillation," the firm states. Initial studies will include 10 patients at four centers. Overseas trials began in October 1995...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel